Protagonist Therapeutics

1. Zasocitinib Takeda filing2026Zasocitinib Takeda filing, 2026, notable
2. MIMRYLO/ICOTYDE commercial launch3Q 2026MIMRYLO/ICOTYDE commercial launch, 3Q 2026, notable
3. DISC-3405 Disc Medicine Ph2 interim3Q 2026DISC-3405 Disc Medicine Ph2 interim, 3Q 2026, notable
4. PTGX buyback corporate updateBy year-end 2026PTGX buyback corporate update, By year-end 2026, routine
5. Takeda/J&J milestone payments FDA decision4Q 2026Takeda/J&J milestone payments FDA decision, 4Q 2026, material
6. PN-881 Ph2b startearly 1Q 2027PN-881 Ph2b start, early 1Q 2027, notable
7. PN-8047 Ph1 start1Q 2027PN-8047 Ph1 start, 1Q 2027, notable
8. PN-477 Ph1 start1H 2027PN-477 Ph1 start, 1H 2027, notable
9. Divesiran Silence Therapeutics Ph3 readout1H 2027Divesiran Silence Therapeutics Ph3 readout, 1H 2027, notable
10. ICOTYDE readoutFeb 2027 – Sep 2028ICOTYDE readout, Feb 2027 – Sep 2028, material
11. PN-8047 Ph1 interimMid-2027PN-8047 Ph1 interim, Mid-2027, material
12. PN-477/PN-8047/PN-458 Ph2 readout2H 2027PN-477/PN-8047/PN-458 Ph2 readout, 2H 2027, material
13. PN-881 readout2H 2027PN-881 readout, 2H 2027, material
14. PN-881 Ph2 topline1H 2028PN-881 Ph2 topline, 1H 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.